Investment Rating - The industry investment rating is "Recommended" [1] Core Insights - The report highlights the impact of escalating trade conflicts on the supply chain of pharmaceuticals, particularly regarding the exemption of certain drugs from tariffs, which reflects the U.S.'s reliance on global pharmaceutical supply chains [3] - The report emphasizes the importance of international markets for Chinese pharmaceutical exports, with a projected export value of $107.96 billion in 2024, indicating a growth of 5.9% year-on-year [4] - The report discusses the potential changes in the supply landscape for blood products due to new tariffs, which may accelerate domestic substitution opportunities [6] - The report notes the ongoing evolution of raw material applications, particularly in the nicotine sector, as companies explore new production avenues [8] - The report indicates that the optimization of centralized procurement policies may alleviate pricing pressures on traditional pharmaceutical companies [10] - The report outlines advancements in CAR-T cell therapies, with significant sales growth and the potential for cost reductions in the future [12] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 2.57 percentage points in the past week, ranking third among 31 primary industry indices [23] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector's index has shown a 3.15% increase over the past month, outperforming the CSI 300 index by 4.20 percentage points [40] - The current PE (TTM) for the pharmaceutical sector is 31.25, which is below the historical average of 32.95 [45] 3. Recent Research Achievements - The report lists various deep-dive studies conducted by the research team, focusing on supply and demand dynamics in the blood products sector and the impact of policy support on inhalation drug markets [49] 4. Important Industry Policies and News - Recent policy updates include the release of the 2025 edition of the Pharmacopoeia of the People's Republic of China, which will take effect on October 1, 2025 [52] - Significant industry news includes the approval of new drug applications by major pharmaceutical companies, indicating ongoing innovation and market activity [54][55]

【深圳商报讯】（记者 陈燕青）一季度公募基金调研热情依然较高。公募排排网数据显示，今年一季 度共有163家公募基金参与到A股公司调研，覆盖到30个申万一级行业中的1074家公司，合计调研次数 达14985次。 一季度公募机构调研覆盖的1074家A股公司中，36家公司被调研次数不少于60次，其中20家被调研60- 79次；13家被调研80-99次；3家被调研不少于100次。一季度公募基金调研前十大A股公司均被调研不 少于88次。其中，机械设备行业公司汇川技术被调研236次居首，大幅领先于其余公司，成为一季度最 受公募调研青睐公司。医药生物行业公司安必平和电子行业公司水晶光电均被调研不少于100次，仅次 于汇川技术。 一季度公募机构调研覆盖的30个申万一级行业中，23个申万一级行业被调研不少于100次，其中10个行 业被调研100-299次。 一季度参与A股公司调研的163家公募机构中，93家公募机构调研次数不少于60次，其中32家公募机构 调研60-99次；48家调研100-199次；13家调研不少于200次。博时基金一季度调研364次居首，成为一季 度调研最勤奋的公募机构，其调研公司中，汇川技术、安必平、水晶 ...

长按即可参与 3、AI医疗产业端落地成熟度，影像→体外诊断→医疗机器人→制药→慢病管理→医疗信息化。 4、AI+诊断领域： 1）体外诊断公司：主业有业绩压力，但需给予AI属性估值溢价。关注与大厂绑定深、落地成熟的 公司。 2）影像公司：如联影，在设备市场铺设、市占率、数据授权上有优势。 3）业绩变好公司：对主业业绩有包容度，关注可能迎来拐点的公司。 风险提示：本文所提到的观点仅代表个人的意见，所涉及标的不作推荐，据此买卖，风险自负。 作者： 巴菲特读书会 来源：雪球 1、AI医疗产业整体前景大，能够赋能医疗产业端公司的传统业务，提升其盈利能力，并在客户绑 定、新客户开拓上提供帮助。 2、在患者端，AI医疗可以提高了医疗资源的可及性，使得偏远地区的人能够触达到高等级的医疗 资源（医疗资源平权）；还可以减少漏诊和误诊，提高诊断的准确性（诊断准确性）；以及AI制 药如果成功，患者将受益（制药）。 4）细分领域数据公司：如华大智造，除数据、AI逻辑外，还受Illumina被禁入中国市场影响。 5、AI+医院/医生：AI能提高医生和医院的诊断治疗能力；对医院和医生的运营效率有帮助。 6、AI+慢病管理：看好AI慢病管理 ...

Group 1: AI in Healthcare Overview - The "AI + Healthcare" trend is gaining momentum, with significant interest from various stakeholders including pharmaceutical giants and diagnostic companies, as well as hospitals and internet healthcare platforms [1] - The "AI + Healthcare" sector is expected to be a major investment opportunity throughout 2025, with related stocks experiencing substantial price increases [1] Group 2: Drug Development Innovations - AI is anticipated to break through bottlenecks in drug development, which has traditionally been a lengthy and costly process with low success rates [4] - Compared to traditional drug development, AI can reduce the time for drug discovery and preclinical research by nearly 40%, and increase the success rate of clinical new drug development from 12% to approximately 14% [5] - AI applications in drug development include drug target discovery, molecular design, compound screening, and clinical trials, significantly enhancing efficiency and reducing costs [5][6] Group 3: AI in Diagnostics - AI platforms like DeepSeek are enhancing diagnostic accuracy and efficiency, providing personalized medication suggestions based on patient data [8] - Over 100 hospitals in China have implemented DeepSeek for various applications, including clinical diagnosis and management [8] - AI technologies are also being utilized in medical imaging for assisting diagnoses, optimizing clinical trial designs, and improving patient management [9] Group 4: Market Performance and Investment - The AI pharmaceutical sector has seen a significant rise, with the sector's cumulative increase reaching 30.96% from February 5 to March 24 [11] - Individual stocks such as Anbiping have experienced remarkable growth, with a cumulative increase of 98.87% during the same period, driven by their involvement in AI [11] - Institutions are optimistic about the growth potential of the "AI + Healthcare" sector, predicting a global market size increase from $13.7 billion in 2022 to $155.3 billion by 2030, with a CAGR of 35.5% [12]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1]. Core Insights - The global new drug business development (BD) remains robust, with approximately 31% of innovative drug candidates introduced by multinational pharmaceutical companies in 2024 coming from China. In the first two months of 2025, there have already been 16 Chinese innovative drug BD projects, expanding from oncology to autoimmune diseases [3]. - The weight loss market is seeing multiple BD agreements, with significant sales figures reported by Novo Nordisk and Eli Lilly. Novo Nordisk's core products generated sales of approximately $27.94 billion in 2024, while Eli Lilly's Mounjaro saw a 124% year-on-year increase in sales to $11.54 billion [5]. - CAR-T cell therapy continues to progress, with global sales expected to reach approximately $4.53 billion in 2024. Chinese companies are also participating in the global CAR-T sales, indicating their technological capabilities [6]. - The gene sequencing industry is accelerating its domestic production capabilities following export restrictions on Illumina's sequencing instruments. Domestic alternatives are rapidly emerging, with several companies receiving regulatory approvals for their sequencing devices [7]. - AI in healthcare is advancing, with various AI models being developed for specific medical fields. Collaborations between tech companies and healthcare providers are enhancing the integration of AI into traditional medical practices [9]. Summary by Sections Industry Trends - The pharmaceutical industry outperformed the CSI 300 index by 0.18 percentage points in the past week, with a weekly increase of 1.77% [23]. - Over the past month, the pharmaceutical sector also outperformed the CSI 300 index by 0.22 percentage points, with a monthly increase of 1.94% [27]. Subsector Performance - The pharmaceutical commercial sector saw the highest weekly increase of 6.44%, while the medical device sector had the lowest at 1.09% [30]. - Over the past year, the chemical pharmaceutical sector had the highest increase of 6.49%, while the biological products sector experienced a decline of 17.62% [37]. Company Recommendations - The report recommends focusing on companies involved in weight loss and NASH, such as Zhongsheng Pharmaceutical, and highlights the potential of companies like Geli Pharmaceutical and Lianbang Pharmaceutical [12]. - Companies engaged in CAR-T technology, such as Kexin Pharmaceutical, are also recommended as they approach market entry [12]. - The report emphasizes the importance of AI integration in medical devices, recommending companies like Anbiping and RunDa Medical for their competitive advantages [12]. Recent Developments - The report notes significant recent financing and regulatory approvals for various companies, indicating a dynamic and evolving market landscape [54][55].

Market Performance - The CSI 2000 index performed well today, while the SSE 50 index fell by 0.49% and the CSI 300 index fell by 0.36%. The CSI 500 index decreased by 0.07%, and the CSI 1000 index increased by 0.23% [5] - Among sector indices, the media, comprehensive finance, telecommunications, computer, and construction industries performed well, with returns of 1.84%, 1.33%, 1.11%, 0.69%, and 0.55% respectively. In contrast, the home appliance, coal, food and beverage, agriculture, forestry, animal husbandry, and pharmaceutical industries performed poorly, with returns of -0.83%, -0.80%, -0.78%, -0.76%, and -0.64% respectively [6] - Concept themes such as China Broadcasting, broadcasting systems, three-network integration, jewelry, and IPV6 performed well, with returns of 7.70%, 6.00%, 4.12%, 4.03%, and 3.75% respectively. Conversely, PTA, cross-strait integration, COVID-19 antigen testing, excavators, and industrial gases performed poorly, with returns of -1.46%, -1.38%, -1.37%, -1.36%, and -1.31% respectively [7] Market Sentiment - Market sentiment was high today, with 94 stocks hitting the daily limit up and 3 stocks hitting the limit down. The highest number of limit up stocks during the day was 102, while the highest number of limit down stocks was 4 [9] - Stocks that were limit up yesterday had a closing return of 2.47% today, while those that were limit down yesterday had a closing return of 1.87% today [10] - The sealing rate was 63%, a decrease of 14% from the previous day, while the consecutive sealing rate was 32%, an increase of 11% from the previous day, marking a new high for the past month [11] Market Capital Flow - As of March 11, 2025, the margin trading balance was 1,922.7 billion yuan, with a financing balance of 1,910.7 billion yuan and a securities lending balance of 12 billion yuan. The margin trading balance accounted for 2.4% of the circulating market value, and margin trading accounted for 9.7% of the market turnover [12][13] Premium and Discount - On March 11, 2025, the ETF with the highest premium was the Bank ETF Preferred, with a premium of 0.99%, while the ETF with the highest discount was the Hong Kong-Shenzhen Technology ETF, with a discount of 1.20% [16] - The average daily transaction amount of block trades over the past six months reached 1.5 billion yuan, with a transaction amount of 1.3 billion yuan on March 11, 2025. The average discount rate over the past six months was 5.20%, while the discount rate on that day was 4.35% [17] - The annualized premium rate for the main contract of the SSE 50 index futures was 1.32% on March 12, 2025, at the 58th percentile for the past year. The annualized discount rates for the CSI 300, CSI 500, and CSI 1000 index futures were 3.67%, 12.71%, and 28.92%, respectively, at the 34th, 11th, and 3rd percentiles for the past year [18] Institutional Attention and Rankings - The stocks with the most institutional research in the past week included Henghui Security, Chip Source Micro, Xiamen Tungsten, and others, with Henghui Security being researched by 147 institutions [19] - The stocks with the highest net inflow from institutional special seats on March 12, 2025, included Meili Technology, Bafang Co., and others, while those with the highest net outflow included Suotong Development, Yunding Technology, and others [20][22]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [4]. Core Views - The government has increased support for innovative drugs, which is expected to promote healthy development across various segments of the pharmaceutical industry [6][32]. - The report emphasizes a positive outlook for the pharmaceutical sector, particularly in the context of recent government policies aimed at enhancing healthcare services and drug innovation [27][32]. Summary by Sections Weekly Market Review - The pharmaceutical and biotechnology index rose by 2.02%, outperforming the CSI 300 index by 0.64 percentage points, ranking 18th in industry performance [9]. - Year-to-date, the index has increased by 6.53%, again surpassing the CSI 300 by 6.3 percentage points, ranking 14th [9]. - Sub-sectors such as medical services and medical devices showed significant gains, with medical services up 3.7% and medical devices up 3.29% for the week [13]. Individual Stock Performance - In the A-share market, 321 out of 477 pharmaceutical stocks rose, with notable gainers including Hotgen Biotech (+38.63%) and Berry Genomics (+34.39%) [18]. - In the Hong Kong market, 78 out of 106 pharmaceutical stocks increased, with top performers being HeartFlow Medical-B (+31.87%) and Hengrui Medicine-B (+30.19%) [22]. Industry News and Policies - The government work report highlighted the need for a collaborative approach to healthcare, emphasizing the integration of medical services, insurance, and pharmaceuticals [27]. - Key policies include optimizing drug procurement, enhancing quality assessments, and increasing financial support for basic medical insurance [33]. Weekly Insights - The report reiterates a bullish stance on the pharmaceutical sector, particularly in light of government initiatives to support innovative drug development and improve healthcare financing [32][34]. - Specific recommendations include focusing on companies in various segments such as raw materials, chemical preparations, and medical services, with suggested stocks like Hengrui Medicine and WuXi AppTec [34].

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 年初以来，在DeepSeek的推动下，各行各行纷纷加入AI浪潮。 近日， 华为 宣布正式成立"医疗卫生军团" ，用AI大模型为中国医院装上"智能心 脏"，提升医疗效率和质量 。该军团旨在整合华为在5G、云计算、AI大模型等领域的技术积累，重点构建AI辅助诊断解决方案体系，推动医疗大模型 在临床场景的应用。 据世界卫生组织预测，到 2030 年全球医疗数据量将增长至 2.3 万亿 GB ，但传统医疗系统对数据的处理能力严重滞后。 华为的医疗军团模式，正是 以技术融合填补这一鸿沟，通过"端到端"的垂直整合 ，实现从实验室到临床的快速落地。 # 三 大核 心 技术底 牌 虽然华为本身并未发布任何医疗大模型，只是为行业训练大模型提供解决方案。但面对这块万亿蛋糕，华为的野心远不止于技术供应商，它要成为医 疗智能化的"操作系统"。 一旦华为在技术、生态、政策三端协同突破，或将推动中国医疗从"跟跑"转向"领跑 "。 华为的"军团制度"自2021年实施以来， ...

Summary of Key Points from the Conference Call Industry Overview - The conference focused on the AI agent's impact on the software industry and its evolution, particularly in the context of the Chinese market and major players like Salesforce, Microsoft, and domestic companies such as Kingsoft and Hancloud [1][2][3][6][11]. Core Insights and Arguments - **AI Agent Capabilities**: AI agents have evolved from traditional language models to capable task executors, enabling them to autonomously manage workflows and replace some human roles [2][5]. - **Development Stage**: The current development level of AI agents is comparable to GPT-3 and ChatGPT, with expert model scores reaching 70%-72% [3][45]. - **Business Model Transformation**: Companies like Salesforce are shifting from service fee models to per-use charging, reflecting a broader trend in the industry as AI agents take over manual tasks [7][8][10]. - **Domestic Market Dynamics**: In China, the demand for customized software solutions has increased, leading to a decline in profit margins for software companies. However, standardized AI agents can meet these customization needs without extensive development [6][11]. - **Investment in AI Infrastructure**: Major companies, including Microsoft and Salesforce, are investing heavily in AI infrastructure and tools, indicating a strong commitment to AI innovation [9][10]. Notable Developments - **Microsoft's Initiatives**: Microsoft established the QAI platform and introduced a pay-per-use model for its 365 Cop Track tool, showcasing its ongoing innovation in AI [9]. - **Salesforce's Expansion**: Salesforce has expanded its AI capabilities across various sectors, including HR and finance, by launching native agents [10]. - **Domestic Companies' Performance**: Kingsoft reported strong performance in its B-end revenue, while companies like Fanwei Network and Hancloud are also making significant strides in AI solutions [11][12]. Additional Important Insights - **Telecom Sector's Role**: Domestic telecom operators are crucial in the AI industry chain, focusing on computing power and transitioning from traditional network operations to computing operations [14][17]. - **Cloud Computing Trends**: The cloud computing and IDC sectors are experiencing a resurgence driven by AI demand, with domestic companies like Alibaba and Tencent seeing significant growth in AI-related revenues [15][77]. - **Emerging AI Applications**: The conference highlighted the potential of AI in various sectors, including healthcare, finance, and education, emphasizing the need for continuous innovation and adaptation [62][63]. Conclusion - The AI agent's development is reshaping the software industry, with significant implications for business models, operational efficiency, and market dynamics. Companies that adapt to these changes and invest in AI capabilities are likely to gain a competitive edge in the evolving landscape.

Investment Rating - The report does not explicitly state an investment rating for the industry [5] Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.06%, underperforming compared to the Wind All A index (2.43%) and the CSI 300 index (1.39%). The AI + healthcare sector experienced a significant rebound [10][11] - Key sectors that performed well include in vitro diagnostics (4.45%), active pharmaceutical ingredients (2.08%), and hospitals (1.85%). Conversely, offline pharmacies (-0.59%) and medical devices (-0.08%) saw declines [10][11] - The government work report emphasized strengthening basic medical and health services, implementing a health-first development strategy, and promoting the coordinated development of healthcare, medical insurance, and pharmaceuticals [12][14] - On March 8, Huawei announced the establishment of a healthcare division, aiming to integrate its expertise in 5G, cloud computing, and edge computing to develop AI-assisted diagnostic solutions [12][14] Weekly Market Review - The pharmaceutical and biotechnology sector increased by 1.06%, lagging behind the Wind All A index (2.43%) and the CSI 300 index (1.39%). The AI + healthcare direction showed a notable rebound [10] - The top-performing sub-sectors included in vitro diagnostics (4.45%), active pharmaceutical ingredients (2.08%), and hospitals (1.85%), while offline pharmacies (-0.59%) and medical devices (-0.08%) were the worst performers [10][11] - The top three gaining stocks were Hotgen Biotech (38.63%), Berry Genomics (34.39%), and Anbiping (25.72%), while the top three losing stocks were Jiangsu Wuzhong (-14.34%), ST Sansheng (-9.83%), and Baile Tianheng-U (-9.44%) [12][14] Industry News and Key Company Announcements - The government work report highlighted the need to enhance basic medical services and improve the healthcare system, including reforms in public hospitals and drug procurement policies [12][14] - Huawei's new healthcare division aims to leverage its technological strengths to accelerate the development of medical AI models for clinical applications [12][14] - On March 8, Ausgen announced that the FDA accepted its new drug application for AUKONTALS, a treatment for amyotrophic lateral sclerosis, with a decision expected by October 23, 2025 [12][14] - CloudTop announced the successful administration of its mRNA personalized cancer vaccine EVM16 in a clinical trial, marking a significant milestone in its development [12][14]